Haider Bin Khaled, MD, a PGY3 internal medicine resident at Geisinger, discusses real-world outcomes with caplacizumab, a monoclonal antibody used to treat immune thrombotic thrombocytopenic purpura (iTTP). The findings were presented in a poster at the SOHO 2026 Annual Meeting in Houston, Texas.
The retrospective study evaluated clinical outcomes and hospital resource utilization among patients hospitalized with iTTP. Researchers compared patients who received caplacizumab plus plasmapheresis with those who received plasmapheresis without caplacizumab. After adjustment, caplacizumab use was not associated with significantly lower inpatient mortality or a reduction in the composite outcome of mortality or thrombotic events.
Major bleeding rates also did not differ significantly between groups. However, caplacizumab use was associated with longer hospital stays and higher hospital charges.

Leave feedback about this